Jochen Wöhrle1, Wolfgang Rottbauer, Armin Imhof. 1. Department of Internal Medicine II, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany. jochen.woehrle@uniklinik-ulm.de
Abstract
BACKGROUND: After successful recanalization of a coronary chronic total occlusion (CTO) the risk for restenosis and subsequent need for repeat intervention is high. Everolimus-eluting stents (EESs) were associated with low rates of restenosis, reintervention and stent thrombosis in non-occluded lesions. We sought to determine the antiproliferative impact of the everolimus-eluting Xience V stent in CTOs. METHODS: Fifty-three patients with a CTO in a native coronary artery were included. CTO was defined as a duration of occlusion ≥3 months and thrombolysis in myocardial infarction 0 flow. EESs were exclusively implanted to completely cover the occluded and adjacent stenotic segments. Dual antiplatelet therapy was prescribed for 6 months. Follow-up angiography was scheduled at 6 months. Clinical follow-up was done at 12 months. The primary endpoint was late loss at the initial occlusion site. Secondary clinical endpoint was a composite of cardiac death, myocardial infarction not clearly attributable to a non-target vessel and target lesion revascularization. RESULTS: Mean occlusion length was 24 ± 17 mm, ranging from 4 to 74 mm. Mean stent length was 79 ± 36 mm, ranging from 18 to 158 mm. Reference diameter was 3.27 ± 0.58 mm. Late loss at the initial occlusion site was 0.22 ± 0.69 mm. There were six (11%) binary restenosis with a target lesion reintervention in three (6%) patients. There was no death, myocardial infarction or stent thrombosis within 12 months. CONCLUSION: In patients with successful recanalization of complex CTOs the use of EESs results in a low angiographic late loss and restenosis rate without stent thrombosis throughout 12 months follow-up.
BACKGROUND: After successful recanalization of a coronary chronic total occlusion (CTO) the risk for restenosis and subsequent need for repeat intervention is high. Everolimus-eluting stents (EESs) were associated with low rates of restenosis, reintervention and stent thrombosis in non-occluded lesions. We sought to determine the antiproliferative impact of the everolimus-eluting Xience V stent in CTOs. METHODS: Fifty-three patients with a CTO in a native coronary artery were included. CTO was defined as a duration of occlusion ≥3 months and thrombolysis in myocardial infarction 0 flow. EESs were exclusively implanted to completely cover the occluded and adjacent stenotic segments. Dual antiplatelet therapy was prescribed for 6 months. Follow-up angiography was scheduled at 6 months. Clinical follow-up was done at 12 months. The primary endpoint was late loss at the initial occlusion site. Secondary clinical endpoint was a composite of cardiac death, myocardial infarction not clearly attributable to a non-target vessel and target lesion revascularization. RESULTS: Mean occlusion length was 24 ± 17 mm, ranging from 4 to 74 mm. Mean stent length was 79 ± 36 mm, ranging from 18 to 158 mm. Reference diameter was 3.27 ± 0.58 mm. Late loss at the initial occlusion site was 0.22 ± 0.69 mm. There were six (11%) binary restenosis with a target lesion reintervention in three (6%) patients. There was no death, myocardial infarction or stent thrombosis within 12 months. CONCLUSION: In patients with successful recanalization of complex CTOs the use of EESs results in a low angiographic late loss and restenosis rate without stent thrombosis throughout 12 months follow-up.
Authors: Carlo Di Mario; Gerald S Werner; Georgios Sianos; Alfredo R Galassi; Joachim Büttner; Dariusz Dudek; Bernard Chevalier; Thierry Lefevre; Joachim Schofer; Jacques Koolen; Horst Sievert; Bernhard Reimers; Jean Fajadet; Antonio Colombo; Anthony Gershlick; Patrick W Serruys; Nicolaus Reifart Journal: EuroIntervention Date: 2007-05 Impact factor: 6.534
Authors: Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes Journal: N Engl J Med Date: 2010-05-06 Impact factor: 91.245
Authors: Gerald S Werner; Andreas Krack; Gero Schwarz; Dirk Prochnau; Stefan Betge; Hans R Figulla Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Humberto J Colmenarez; Javier Escaned; Cristina Fernández; Liliana Lobo; Sara Cano; Juan G del Angel; Fernando Alfonso; Pilar Jimenez; Camino Bañuelos; Nieves Gonzalo; Eulogio García; Rosana Hernández; Carlos Macaya Journal: J Am Coll Cardiol Date: 2010-04-27 Impact factor: 24.094
Authors: Antoinette de Waha; Salvatore Cassese; Duk-Woo Park; Francesco Burzotta; Robert A Byrne; Tomohisa Tada; Lamin A King; Seung-Jung Park; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2012-03-16 Impact factor: 5.460
Authors: Alexander Sedaghat; Jan-Malte Sinning; Kathrin Paul; Gregor Kirfel; Georg Nickenig; Nikos Werner Journal: Clin Res Cardiol Date: 2013-02-10 Impact factor: 5.460
Authors: Koen Teeuwen; Tom Adriaenssens; Ben J L Van den Branden; José P S Henriques; Rene J Van der Schaaf; Jacques J Koolen; Paul H M J Vermeersch; Mike A R Bosschaert; Jan G P Tijssen; Maarten J Suttorp Journal: Trials Date: 2012-12-15 Impact factor: 2.279
Authors: Liefke C van der Heijden; Marlies M Kok; Ming Kai Lam; Peter W Danse; Alexander R Schramm; Gillian A J Jessurun; R Melvyn Tjon Joe Gin; K Gert van Houwelingen; Raymond W M Hautvast; Gerard C M Linssen; Hanim Sen; Marije M Löwik; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen Journal: Clin Res Cardiol Date: 2015-09-02 Impact factor: 5.460